Irodalom
1. Ardizzone S. Is maintenance therapy always necessary for patients with ulcerative colitis in
remission? Aliment Pharmacol Ther 1999;13:373-379
2. Barthet M. Chronic pancreatitis and inflammatory bowel disease: true or coincidal
association? Am J Gastroenterol 1999;94:2141-2148
3. BelaicheJ. Acute lower gastrointestinal bleeding in Crohn’s disease: characteristics of a
unique series of 34 patients. Am J Gastroenterol 1999;2177-2181
4. Box JC. Clinical implications of multiple colorectal carcinomas in heretitary nonpolyposis
colorectal carcinoma. Dis Colon Rectum 1999;42:717-721
143
5. Bronk MA. Enterohepatic cycling of bilirubin: a putative mechanism for pigment gallstone
formation in ileal Crohn’s disease. Gastroenterology 1999;116:1420-1427
6. Bus PJ. Mesalazine-induced apoptosis of colorectal cancer: on the verge of a new
chemopreventive era? Aliment Pharmacol Ther 1999;13:1397-1402
7. Camilleri M. Improvement in pain and bowel function in female irritable bowel patientes with
alosetron, a 5-HT3 receptor antagonist. Aliment Pharmacol Ther 1999;13:1149-1159
8. Campieri M. Probiotics in inflammatory bowel disease: a new insight to pathogenesis or a
possible therapeutic alternative? Gastroenterology 1999;116:1246-1249
9. Casson DH. Low-dose intravenous azathioprine may be effective in the manegement of acute
fulminant colitis complicating inflammatory bowel disease. Aliment Pharmacol Ther
1999;13:891-895
10. Cohen RD. Intravenous cyclosporin in ulcerative colitis: a five-year experience. Am J
Gastroenterol 1999;94:1587-1592
11. Colombel J-F. A controlled trial comparing ciprofloxacin with mesalazine for the treatment
of active Crohn’s disease. Am J Gastroenterol 1999;94:674-678
12. Cosnes J. Effects of current and former cigarette smoking on the clinical course of Crohn’s
disease. Aliment Pharmacol Ther 1999;1403-1411
13. D’Haens G. Endoscopic and histological healing with infliximab anti-tumor necrosis factor
antibodies in Crohn’s disease: a European multicenter trial. Gastroenterology
199;116:1029-1034
14. D’Haens GR. Duration of response following cessation of Infliximab therapy for active or
fistulizing Crohn’s disease. Gastroenterology 1999;116:A696
15. Diskstra B. Protektíve effect of appendectomy on the development of ulcerative colitis. Dis
Colon Rectum 1999;42:334-336
16. Dinca M. Evolution of osteopenia in inflammatory bowel disease. Am J Gastroenterol
1999;94:1292-1297
17. Dowd J. Ischaemic colitis assiciated with pseudoepinephrin: four cases. Am J Gastroenterol
1999;94:2430-2434
18. Drossmann DA. The functional gastrointestinal disorders and the Rome II process. Gut
1999;45(Suppl II):II1-II5
19. Egan LJ. A randomized dose-response and pharmacokinetic study of methotrexate for
refractory inflammatory Crohn’s disease and ulcerative colitis. Aliment Pharmacol Ther
1999;13:1597-1604
20. Elsenbruch S. Subjective and objective sleep quality in irritable bowel syndroma. Am J
Gastroenterol 1999;94:2447-2452
21. Gaelazzi F. Cigarette smoke aggravates experimental colitis in rats. Gastroenterology
1999;117:877-883
22. Geerling BJ. Nutrition and inflammatory bowel diseae: an update. Scand J Gastroenterol
1999;34:95-105
23. Gionchetti P. Antibiotic combination therapy in patients with chrinic, treatment-resistant
pouchitis. Aliment Pharmacol Ther 1999;13:713-718
24. Hearing SD. Predivting therapeutic outcome in severe ulcerative colitis by measuring in
vitro steroid sensitivity of proliferating peripherial blood lymphocytes. Gut 1999;45:382-388
25. Hellers G. Oral budesonide for prevention of postsurgical recurrence in Crohn’s disease.
Gastroenterology 1999;116:294-300
26. Ikeda Y. Cancer and adenomatous polyp distribution in the colorectum. Am J Gastroenterol
1999;94:191-193
27. Inoue S. Characterization of cytokine expression in the rectal mucosa of ulcerative colitis:
correlation with disease activity. Am J Gastroenterol 1999;94:2441-2446
144
28. Jones RH. Alosetron relieves pain and improves bowel function compared with mebeverin
in female nonconstipated irritable bowel syndrome patients. Aliment Pharmacol Ther
1999;13:1419-1427
29. Kaiser GC. Mesalamine blocks tumor necrosis factor growth inhibition and nuclear factor
κB activation in mouse colonocytes. Gastroenterology 1999;115:602-609
30. Karlén P. Increased risk of cancer in ulcerative colitis: a population based cohort study. Am
J Gastroenterol 1999;94:1047-1052
31. Kim JC. Distribution of carcinoembryonic antigen and biologic behavior in colorectal
carcinoma. Dis Colon Rectum 1999;42:640-648
32. Koutroubakis IE. Appendectomy, tonsillectomy and risk of inflammatory bowel disease. Dis
Colon Rectum 1999;42:225-230
33. Lamers CBHW. Azathioprine: an update on clinical efficacy and safety in inflammatory
bowel disease. Scand J Gastroenterol 1999;34 Suppl 230:111-115
34. Lapidus A. The prevalence of gallstone disease in a defined cohort of patients with Crohn’s
disease. Am J Gastroenterol 1999m,94:1261.1266
35. Lashner BA. Evolution of the usefulness of testing for p53 mutations in colorectal cancer
surveillance for ulcerative colitis. Am J Gastroenterol 1999;94:456-462
36. Lee OY. Impact of advertisment and clinic populations in symptoms and perception of
irritable bowel syndrome. Aliment Pharmacol Ther 1999;13:1631-1638
37. Loundon CP. The effects of physical exercise on patients with Crohn’s disease. Am J
Gastroenterol 1999;94:697-703
38. Lysy J. The prevalence of chronic diarrhea amióong diabetic patients. Am J Gastroenterol
1999;94:2165-2170
39. Madsen KL. Lactobacillus species prevents colitis in interleukin 10 gene-deficient mice.
Gastroenterology 1999;116:1107-1117
40. Mayer R. Colorectal cancer in inflammatory bowel disease. Dis Colon Rectum
1999;42:343-347
41. Mertz H. Symptoms and physiology in severe chronic costipation. Am J Gastroenterol
1999;94:131-138
42. Montgomery SM. Paramyxovirus infections in childhood and subsequent inflammatory
bowel disease. Gastroenterology 1999;116:796-803
43. Moum B. Change in the extent of colonoscopic and histological involvement in ulcerative
colitis over time. Am J Gastroenterol 1999;94:1564-1569
44. Nagata C. Cigarette smoking, alcohol use and colorectal adenoma in japanese men and
women. Dis Colon Rectum 1999;42:337-342
45. Netzer P. Frequency of advanced neoplasia in the proximal colon without an index poyp in
the rectosigmoid. Dis Colon Rectum 1999;42:661-667
46. Neurath MF. Randomised trial of mycophenolate mofetil versus azathioprine for treatment
of chronic active Crohn’s disease. Gut 1999;44:625-628
47. Park JG. Suspected hereditary nonpolkyposis colorectal cancer. International collaborative
group on HNPCC criteria and result of genetic diagnosis. Dis Colon Rectum 1999;42:710-716
48. Ponec RJ. Neostigmine for the treatment of acute colonic pseudo-obstruction N Engl J Med
1999;341:137-141
49. Ponz de Leon M. Hereditary colorectal cancer in the general population: from cancer
registration to molecular diagnosis. Gut 1999;45:32-38
50. Prantera C. Mesalamine in the treatment of mild to moderate active Crohn’s ileitis: Results
of a randomised, multicenter study. Gastroenterology 1999;115:521-526
51. Present DH. Infliximab for the treatment of fistulas in patients with Crohn’s disease. N Engl
J Med 1999;341:1398-1405
145
52. Prior TW. The I1307K polymorphism of the APC gene in colorectal cancer
Gastroenterology 1999;116:58-63
53. Rachmilewitz D. On smoking, rats, and inflammatory bowel disease. Gastroenterology
1999;117:1008-1011
54. Rawsthorne P. An international survey of the use and attitudes regarding alternative
medicine by patients with inflammatory bowel disease. Am J Gastroenterol 1999;94:1298-1303
55. Riegler G. Prevalence of HNPCC in a series of consecutive patients on the first endoscopic
diagnosis of colorectal cancer: a multicenter study. Endoscopy 1999;31:337
56. Rothstein KD. Percutaneous microwave coagulation therapy: another option for the
treatmnent of hepatic metastases. Am J Gastroenterol 1999;94:299.300
57. Rozen P. Prevalence of the I1307K APC gene variant in israeli Jews of differing ethnic
origin and risk for colorectal cancer. Gastroenterology 1999;116:54-57
58. Ruigómez A. One-year follow-up of newly diagnosed irritable bowel syndrome patients.
Aliment Pharmacol Ther 1999;13:1097-1102
59. Rutgeerts P. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody
(infliximab) to maintain remission in Crohn’s disease. Gastroenterology 1999;117:761
60. Sandborn WJ. Lack of effect of intravenous administration on time to respond to
azathioprine for steroid treated Crohn’s disease. Gastroenterology 1999;117:527-535
61. Sands BE. Preliminary evaluation of safety and activity of recombinant human interleukin 11
in patients with active Crohn’s disease Gastroenterology 1999;117:58-64
62. Schechter S. Management of uncomplicated acute diverticulitis. Dis Colon Rectum
1999;42:470-476
63. Schulte C. Bone loss in patients with inflammatory bowel disease is lett than expected: a
follow-up study. Scand J Gastroenterol 1999;34:696-702
64. Stack WA. Immunosuppressive therapy for ulcerative colitis: results of a nation-wide survey
among consultant physician members of the British Society of Gastroenterology. Aliment
Pharmacol Ther 1999;13:569-575
65. Seki T. Percutaneous microwave coagulation therapy for solitary metastatic liver tumors
from colorectal cancer: a pilot clinical study. Am J Gastroenterol 1999;94:322-327
66. Sugi K. Antineutrophil cytoplasmatic antibodies in Japanese patients with inflammatory
bowel disease: prevalence and recognition of putative antigens. Am J Gastroenterol
1999;94:1304-1312
67. Thiis-Evensen E. Population-based surveillance by colonoscopy: effect on the incidence of
colorectal cancer. Telemark polyp study I. Scand J Gastroenterol 1999;34:414-420
68. Thompson WG. Functional bowel disorders and functional abdominal pain. Gut
1999;45(Suppl II):II43-II47
69. Todoroki I. Cholecystectomy and the risk of colon cancer Am J Gastroenterol 1999;94:41-46
70. Tomlinson I. Inherited sosceptibility to colorectal adenomas and carcinomas: evidence for a
new predisposition gene on 15q14-q22. Gastroenterology 1999;116:789-795
71. Törkvist L. Low molecular weight heparin as adjuvant therapy in active ulcerative colitis.
Aliment Pharmacol Ther 1999;13:1323-1328
72. van der Sluys Weer A. Faecal parameters in the assessment of activity in inflammatory bowel
disease. Scand J Gastroenterol 1999;34 Suppl 230:106-110
73. van Gorkom BAP. Review article: anthranoid laxatives and their potential carcinogenic
effects. Aliment Pharmacol Ther 1999;13:443-452
74. Vrij AA. Low molecular weight heparin (LMWH) threatment in steroid refractory ulcerative
colitis. Gastroenterology 1999;116:A841
75. Weinberg DS. Risk for colorectal cancer after gynecologic cancer. Ann Intern Med
1999;131:189-193
76. Wessely S. Functional somatic syndromes: one or many? Lancet 1999;354:936-939
77. Whitehead WE. Functional disorders of the anus and rectum. Gut 1999;45(Suppl II):II55-II59
